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Abstract
Introduction: Sparse data are available about the effect of therapy methods on antibody levels in patients with liver failure. The aim of this study 
was to determine serum immunoglobulin concentrations in patients with chronic hepatic failure (CHF), acute- (ALF), or acute-on-chronic liver failure 
(ACLF) and to evaluate the impact of MARS treatment or liver transplantation (LT) on antibody levels. 
Materials and methods: We followed ten patients with ALF, twelve with ACLF and 18 with CHF. Eight patients with ALF and seven with ACLF un-
derwent MARS therapy, whereas the rest received LT. 13 healthy volunteers served as controls. Serum antibody concentrations were measured using 
ELISA-technique.
Results: Median serum levels of IgA, IgG and IgM were significantly increased in patients with CHF compared to ALF or controls (P < 0.02, P < 0.01, 
and P < 0.01). IgM and IgG concentrations were also significantly elevated in patients with CHF compared to ACLF (IgM, 3.7 vs. 1 g/L, P < 0.001; IgG, 
8.7 vs. 3.1 g/L, P = 0.004). Immediately after LT a significant decrease of IgA (6.9 vs. 3.1 g/L, P = 0.004), IgG (8.7 vs. 5.1 g/L, P = 0.02) and IgM (3.7 vs. 
1.8 g/L, P = 0.001) was detected in patients with CHF and antibody levels further decreased the days after LT reaching levels comparable to healthy 
individuals. MARS treatment had no apparent effect on the immunoglobulin profile in patients with ALF or ACLF. 
Conclusion: We provide evidence that LT reverses hypergammaglobulinemia in patients suffering from CHF within one day, which could be explai-
ned to a reconstituted hepatic antibody clearance, whereas MARS treatment has no immediate effect on immunoglobulin levels.
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Chronic hepatic failure (CHF) and cirrhosis are 
mostly caused by chronic hepatitis C, alcohol 
abuse, or non-alcoholic fatty liver disease and are 
leading causes of morbidity and death (1). Most 
patients suffering from cirrhosis are asymptomatic 
over a long period of time until, e.g. variceal bleed-
ing and bacterial peritonitis cause decompensa-
tion leading to ascites, encephalopathy, portal hy-
pertension, and hepatorenal syndrome (2). A com-
mon observation in patients suffering from CHF is 
the occurrence of hypergammaglobulinemia, de-
scribed for the first time in the early 1970s (3). 
These elevated immunoglobulin concentrations 
even seem to add to the pathogenesis of hepatic 
fibrosis (4). Immunoglobulin serum levels correlate 
with histological findings of advanced forms of he-
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patic fibrosis as well as with the progression of liv-
er disease (5,6) and may add to the compromised 
immune status (2). Thus liver transplantation (LT) is 
the ultimate therapy for patients when standard 
therapy has failed and liver dysfunction is irrevers-
ible (2). According to the United Network of Organ 
Sharing (UNOS) only 6,000 liver transplantations 
are performed every year in the United States and 
about 16,000 patients are currently awaiting trans-
plantation (7).
In contrast to CHF, acute liver failure (ALF) is the 
clinical manifestation of a sudden and severe liver 
damage and acute-on-chronic liver failure (ACLF) 
describes a sudden exacerbation of liver dysfunc-
tion in patients with pre-existing hepatic disease. 
Despite continuous research and improvement in 
intensive care, ALF and ACLF still represent life 
threatening conditions, associated with mortality 
rates up to 60% (8,9). Patients suffering from acute 
liver dysfunction are especially susceptible to in-
fections, due to multiple immunologic defects re-
sulting either from hepatic dysfunction as well as 
from side effects of the high dependency care 
they receive. About half of those patients recover 
spontaneously after intensive care, which also in-
cludes the application of artificial liver assist devic-
es like the molecular adsorbent recirculating sys-
tem (MARS) (10). Those devices were developed to 
support or bridge hepatic function especially in 
patients with an acute exacerbation of hepatic 
dysfunction. In contrast to patients suffering from 
CHF, only a few patients with acute liver dysfunc-
tion undergo LT as ultimate therapy. Several days 
after LT, hypogammaglobulinemia can occur, add-
ing to overall mortality in transplant recipients by 
increasing the risk of postoperative infection 
(11,12). 
In our pilot study we investigated serum immuno-
globulin levels in patients suffering from chronic, 
acute or acute-on-chronic liver failure and com-
pared the concentrations to healthy probands, 
who served as controls. We further studied the im-
mediate effect of LT on immunoglobulin levels in 
patients with CHF and ALF/ACLF to assess sepa-
rately prompt changes in postoperative antibody 
concentrations. Furthermore, we compared im-
munoglobulin serum levels before and after treat-
ment with the artificial liver assist device MARS, 
since immunoglobulin elimination by the MARS 
system seems likely.
Materials and methods
Patients and clinical features
The study was approved by the institutional ethics 
committee and is in accordance with the Helsinki 
Declaration of 1975. After informed consent, sam-
ples were prospectively collected within one year 
and retrospectively analyzed. We followed ten pa-
tients with ALF, twelve patients with ACLF, and 18 
patients suffering from CHF. 13 healthy volunteers 
(10 male / 3 female, range age 21–56, median age 
25) served as controls. Liver diseases, abdominal 
pain over the last four weeks, food intake within 
the last six hours, or pregnancy have been exclud-
ed in the control group via anamnesis. The pa-
tients’ diagnosis, baseline demographics and ini-
tial laboratory values are shown in Table 1. Pre- 
and postoperative liver parameters of all patients 
who underwent LT are given in Table 2 and 3. 
CHF was characterized by the continuous fibrosis 
of liver tissue due to chronic liver damage over a 
longer time period (1). As a consequence, liver 
function got increasingly impaired and fibrotic 
changes finally led to cirrhosis, apparent among 
others by massive ascites at the end-stage of CHF. 
ALF was defined with the onset of coagulopathy 
with international normalized ratio (INR) of greater 
than 1.5 and mental alteration in a patient without 
pre-existing liver cirrhosis and with an illness of 
less than 26 weeks duration (13). Patients suffering 
from ALF were susceptible to develop severe com-
plications, like cerebral oedema, due to an im-
paired protein synthesis of the liver, in turn indicat-
ing a loss of liver function of about 80%. ACLF was 
defined as acute deterioration of liver function fol-
lowed by other end organs in a patient with previ-
ously compensated chronic liver disease (9). A pri-
or episode of decompensation was no exclusion 
criterion in this group. 
In our study eight patients with ALF and seven 
with ACLF were treated with MARS. MARS is a two-
circuit detoxification system to remove albumin-
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Partial liver resection 1
Liver metastasis 1 1
Wilson’s disease 1 1
Hereditary hemorrhagic telangiectasia 1
Haemochromatosis 1
Autoimmune hepatitis 1
Primary biliary cirrhosis 1
Hepatitis C cirrhosis 5 5
Alcoholic liver cirrhosis 1 10
Hepatocellular carcinoma
(chronic Hepatitis B) 3
Gender (male / female) 5 / 5 8 / 4 13 / 5
Age 33 (18-62) 55 (27-67) 57 (47-66)
Underwent LT 2 5 18
Underwent MARS 8 7
Survived / Died 5 / 5 7 / 5 16 / 2
Bilirubin (µmol/L) 266 (64-750) 80 (2-313) 32 (6-233)
Creatinine (µmol/L) 139 (67-347) 95 (34-344) 93 (50-680)
AST (U/L) 635 (72-5771) 219.5 (27-10973) 60 (28-672)
ALT (U/L) 339 (22-3997) 152 (19-6646) 33 (11-538)
PT (% activity) 28 (< 5-71) 50 (21-> 150) 58.5 (21-94)
Data are given as median and range.
AST - aspartate aminotransferase; ALT - alanine aminotransferase; PT - prothrombin time; LT - liver transplantation; MARS - molecular 
adsorbent recirculating system.
Table 1. Underlying liver disease, baseline demographic data and initial laboratory variables
post LT d1 d2 d3 d4 d5
Bilirubin (µmol/L) 47 (12-157) 84 (16-238) 65 (10-274) 65 (10-256) 76 (20-262) 60 (20-314)
Creatinine (µmol/L) 91 (58-278) 122 (7 -217) 114 (73-207) 89 (60-188) 88 (58-249) 90 (59-178)
AST (U/L) 701 (97-5377) 777 (291-6763) 481 (136-4943) 169 (62-1802) 128 (38-596) 136.5 (26-239)
ALT (U/L) 461 (74-3476) 886 (229-4201) 713 (183-6000) 550 (156-6470) 428 (106-2782) 307.5 (66-1450)
PT (% activity) 39.5 (17-90) 39 (11-80) 60 (7-133) 65 (17-119) 63.5 (32-96) 62.5 (36-88)
Data are given as median and range, preoperative values are shown in table 1.
CHF - chronic hepatic failure; AST - aspartate aminotransferase; ALT - alanine aminotransferase; PT - prothrombin time; LT - liver 
transplantation; d1–d5, day 1 to day 5 postoperative.
Table 2. Laboratory values in all patients suffering from CHF who underwent LT (18 patients).
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pre LT post LT d1 d2 d3 d4 d5
Bilirubin 
(µmol/L) 202 (2-750) 142 (16-263) 112 (13-183) 70 (15-202) 69 (14-286) 154 (18-285) 95 (21-275)
Creatinine 
(µmol/L) 92 (34-347) 98 (75-453) 124 (78-683) 103 (65-355) 88 (58-209) 82 (53-181) 112 (57-193)
AST (U/L) 635 (27-10973) 1190 (488-6117) 1639 (314-3454) 875 (183-2190) 262 (88-920) 196 (78-436) 89 (54-245)
ALT (U/L) 488 (29-6646) 999 (358-4260) 1143 (358-2183) 1139 (304-2018) 829 (212-1418) 736 (219-913) 467 (117-591)
PT (% 
activity) 23 (<5->150) 40 (31-96) 48 (27-88) 50 (23-88) 69 (11-87) 80 (21-97) 73 (29-88)
Data are given as median with range.
ALF - acute liver failure; ACLF - acute-on-chronic liver failure; CHF - chronic hepatic failure; AST - aspartate aminotransferase; ALT - 
alanine aminotransferase; PT - prothrombin time; LT - liver transplantation; d1–d5, day 1 to day 5 postoperative.
Table 3. Laboratory values in all patients suffering from ALF or ACLF who underwent LT (7 patients).
bound molecules like bilirubin and ammonia (14), 
and has been shown to improve renal function, 
systemic hemodynamic and hepatic encephalopa-
thy (15). Indications for MARS therapy were ammo-
nia levels of 100 μmol/L or higher with hepatic en-
cephalopathy grade 3. Each eligible patient re-
ceived 1 to 5 MARS treatments lasting 15-22 hours. 
The treatment was conducted via a conventional 
hemodialysis catheter (14), a dialysis machine 
equipment (BM 25, Edwards Life Sciences, Irvine, 
CA, USA), and a highly permeable dialyzer (MARS-
Flux, Gambro, Lund, Sweden). The MARS cycle was 
filled with a 20% human albumin solution and the 
blood flow from the dialysis machine and the al-
bumin dialysate circuit were equal, at rates of 120-
150 mL/min. Prostaglandin I2 (3-5 ng/kg/min) was 
applied continuously extracorporeal after the 
blood pump of the MARS circuit. To maintain the 
activated clotting time between 120 and 140 sec-
onds unfractioned heparin was adjusted if re-
quired by the intensivist on duty (16). 
All patients with CHF, two patients with ALF, and 
five with ACLF included in our study underwent LT. 
Patients with CHF suffered from end stage liver 
disease receiving LT and were clinically stable at 
the time of blood sampling. After LT all patients re-
ceived immunosuppressive medication following 
the center-specific standard therapy, starting with 
an intraoperative dose of 200 mg methylpred-
nisone followed by a steroid taper and withdrawal 
after 3 months. Further, all patients received in-
duction with 2.5 mg per kilogram bodyweight thy-
moglobulin (2.5 mg/kgBW/d) for three days, start-
ing immediately after transplantation. The begin-
ning of maintenance immunosuppression with 
low-dose cyclosporine (trough level 130-150 ng /
mL for month 1, 100-130 ng/mL month 2-3, < 100 
ng/mL beyond month 3) was delayed for 3-4 days. 
Patients suffering from Hepatitis B additionally re-
ceived 10000 IE Hepatect medication during LT as 
well as on 7 postoperative days. Hepatect medica-
tion consists of human hepatitis B immunoglobu-
lins (IgG only).
Laboratory data
A venous blood sample was initially obtained from 
each patient before LT or the first MARS treatment 
as well as from healthy controls. From 15 patients 
suffering from ALF or ACLF another sample was 
taken immediately after detaching the patient 
from the MARS system after the first treatment 
with the artificial liver support system. Venous 
blood from patients who underwent LT was ob-
tained directly before and immediately after trans-
plantation, as well as on five following days after 
the procedure. Right after collection in a 9 mL Z 
Serum Clot Activator Tube (Greiner Bio-One Inter-
national GmbH, Austria), blood was allowed to clot 
for up to 60 minutes at room temperature (22 °C) 
and afterwards centrifuged at 2000 RCF for 10 min 
at 4 °C. Serum aliquots were transferred in tubes 
and stored at −70 °C until further analyzed within 
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the next months. Samples were thawed once si-
multaneously and randomized before analysis. Im-
munoglobulin levels were determined by using 
the Human Immunoglobulin ELISA Quantitation 
Set of Bethyl Laboratories (Montgomery, Texas, 
US) according to the manufacturer instruction. 
Color reaction was gained adding tetramethylben-
zidin (TMB; Sigma, St. Louis, Missouri, US, www.sig-
maaldrich.com) and stopped with 1% sulfuric acid 
solution (in aqua bidest. diluted 95–98% sulfuric 
acid, Merck KGaA, Darmstadt, Germany). The opti-
cal density was measured with a microplate reader 
(Victor 3, Perkin Elmer, Waltham, US) at a wave-
length of 450 nm. Coefficients of variation of the 
used ELISA sets are according to the manufacturer: 
0.4–9.8% for IgA, 0.3–15.4% for IgM, 0.3–3.5% for 
IgG, and 0.6–4.2% for IgE. IgG, IgM and IgA serum 
levels were quantified in gram per liter (g/L) and 
IgE in nanogram per milliliter (ng/mL). 
Following additional parameters were determined 
via routine tests and in the course of routine clini-
cal work: aspartate aminotransferase, alanine ami-
notransferase, bilirubin, serum creatinine, and pro-
thrombin time. The aminotransferases were deter-
mined via enzymatic reaction with pyridoxal phos-
phate according to the recommendations of the 
German Society for Clinical Chemistry (17). Biliru-
bin was quantified via diazotization and creatinine 
with the Jaffe reaction (18). The prothrombin time 
was measured with a coagulometer according to 
Quick et al. (19) and Barthels et al. (20). All parame-
ters were routinely quantified at a certified labora-
tory in the Department of Laboratory Medicine at 
the Medical University of Vienna.  
Statistical analysis
Immunoglobulin levels were compared between 
healthy individuals and patients suffering from 
CHF, ACLF and ALF before transplantation or the 
first MARS treatment. Gaussian distribution was 
assessed with the Shapiro-Wilk normality test. 
Since Gaussian distribution could not be verified 
for all analyzed groups, especially for that with 
fewer patients, the non-parametric Mann-Whit-
ney-test (two-tailed) was used to compare initial 
immunoglobulin concentrations. According to the 
Bonferroni adjustment for multiple comparisons, 
an individual P < 0.013 was necessary to achieve 
statistical significance at the 5% level. The immu-
noglobulin concentrations in patients with ALF or 
ACLF under MARS treatment, as well as globulin 
levels before and after LT were compared using 
paired Wilcoxon’s signed rank tests (two-tailed). A 
P < 0.05 was necessary to achieve statistical signifi-
cance at the 5% level. Correlation between immu-
noglobulin levels and liver enzymes were calculat-
ed in patients suffering from CHF by using Spear-
man’s correlation coefficient. Unless otherwise 
stated data are given as median with range. Statis-
tical analysis was performed using GraphPad Prism 
Version 5.01 (GraphPad Software, Inc. California, 
US).
Results
Initial serum immunoglobulin levels in 
patients with ALF, ACLF, or CHF
In patients suffering from CHF initial serum IgG 
and IgM levels were significantly increased in com-
parison to ALF, ACLF or healthy individuals (8.67 vs. 
3.18, 3.11 or 4.44 g/L for IgG, 3.71 vs. 0.74, 0.95 or 
1.54 g/L for IgM), (Figure 1A and 1B). Increased IgA 
serum levels were found in patients suffering from 
CHF as compared to patients with ALF or controls 
(6.86 vs. 1.72 or 2.51 g/L), (Figure 1C). However, no 
significant difference could be found for IgE serum 
levels. Healthy individuals had a median IgE serum 
concentration of 96 ng/mL (range 28–381), pa-
tients with ALF 429 ng/mL (range 49–11842), with 
ACLF 131 ng/mL (range 30–502) and with CHF 75 
ng/mL (range 23–1667). 
Impact of LT or MARS treatment on serum 
immunoglobulin levels
In patients suffering from CHF a significant de-
crease in serum IgG, IgM and IgA levels could be 
observed immediately after liver transplantation 
(8.67 vs. 5.06 g/L for IgG, 3.71 vs. 1.77 g/L for IgM, 
6.86 vs. 3.07 g/L for IgA) and the first postoperative 
day, (Figure 2). Further, serum immunoglobulin 
levels on the second to the fifth postoperative day 
differed significantly as compared to preoperative 
values (P < 0.001, P = 0.011, 0.009, 0.008 for IgG; P = 
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Figure 1. IgG (A), IgM (B) and IgA (C) serum levels in all pa-
tients suffering from chronic hepatic failure (CHF), acute (ALF) 
or acute-on-chronic liver failure (ACLF), as well as from healthy 
individuals (13 volunteers). Each dot represents an individual 
patient. The line indicates the median. Only significant P values 
are specified. 













































Figure 2. Immunoglobulin levels in patients with chronic he-
patic failure (18 patients) before and after liver transplantation 
(LT) as well as on five following days (d1-d5). Median with range. 
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0.003, 0.003, 0.001, 0.008 for IgM; P < 0.001, P = 
0.002, 0.002, 0.008 for IgA). To reveal errors due to 
peri- and postoperative administered Hepatect 
medication (human IgG), three patients suffering 
from Hepatitis B were tentatively excluded from 
the statistic calculation, with no obvious effects on 
significance. Therefore all values given in Tables or 
Graphs include all patients of the stated group, 
also those suffering from Hepatits B. For the sake 
of completeness, P values for IgG serum levels of 
the patient collective without Hepatect medica-
tion were as followed: 0.041 immediately after LT, 
and 0.005, < 0.001, 0.032, 0.023, and 0.031 on five 
postoperative days as compared to preoperative 
concentrations. For IgE no significant changes af-
ter LT could be detected. IgE serum levels immedi-
ately after LT and on five following days were 58 ng/
mL (range 32–842), 86 ng/mL (range 31–855), 89 ng/
mL (range 27–860), 104 ng/mL (33–908), 124 ng/mL 
(range 31–800) and 102 ng/mL (range 32–740). 
In seven patients with ALF or ACLF who under-
went LT no significant changes in immunoglobulin 
serum concentrations were observed (Table 4). 
In a subgroup of 15 patients with ALF or ACLF im-
munoglobulin measurements were performed 
immediately before and after the first MARS ses-
sion, whereby no obvious effect of the treatment 
on immunoglobulin serum concentrations could 
be detected. Median serum immunoglobulin lev-
els before and after MARS treatment are shown in 
Table 4.
Correlation of immunoglobulin 
concentrations with liver parameters
A significant positive correlation in patients suffer-
ing from CHF can be found for preoperative biliru-
bin and IgM serum concentrations with a P value < 
0.05 and a correlation coefficient of 0.534. IgG se-
rum levels show a significant correlation to albu-
min levels immediately after LT (P = 0.026, r = 
0.523) and on the fifth day after operation (P = 
0.023, r = 0.779). For IgA a significant negative cor-
relation was found to creatinine concentrations on 
the first postoperative day with a P of 0.031 and a 
correlation coefficient of –0.524. IgE values signifi-
cantly correlate with bilirubin levels postoperative 
(P = 0.017, r = 0.588), on the first (P = 0.012, r = 
0.632) and the second day after LT (P = 0.025, r = 
0.575).
Discussion
Our data show increased immunoglobulin serum 
concentrations in patients suffering from CHF in 
comparison to healthy individuals, or patients with 
ALF or ACLF. We further found a decrease in immu-
noglobulin serum levels in patients with CHF im-
mediately after LT, whereas in patients with ALF or 
ACLF no comparable effect was observed. In addi-
tion we could demonstrate that MARS treatment 
has no apparent effect on the immunoglobulin 
profile in patients suffering from acute liver dys-
function. 
Hypergammaglobulinemia is frequently observed 
in patients suffering from CHF. A reason for this 
finding might be either the reduced liver clearance 
of antigens via the portal venous system leading 
to an increased systemic antibody production 
(21,22) or the impaired removal of antibodies by 
the diseased liver (23). Immunoglobulins also 
seem to play an important role in the pathogene-
sis of hepatic fibrosis as exposure to IgG stimulates 
the differentiation and proliferation of hepatic 
stellate cells (4), the major cell type in the develop-
ment of liver fibrosis. In patients with CHF serum 
immunoglobulin concentration even correlates 
with histological findings of advanced forms of he-
patic fibrosis (6), with more elevated levels in pa-
tients with decompensated cirrhosis as compared 
to patients with compensated CHF (5). In accord-
ance to literature, our data also show increased im-
munoglobulin serum levels in patients suffering 
from CHF as compared to ALF or healthy individu-
als. Antibody levels were also significantly elevat-
ed in patients with CHF in comparison to patients 
with an acute exacerbation of an initial chronic liv-
er disease. 
In contrast to CHF, ALF and ACLF are caused by the 
abrupt onset of liver dysfunction. Patients suffer-
ing from ALF or ACLF are highly vulnerable for in-
fections, due to multiple immunological defects, 
influencing hepatic injury as well as the progres-
sion of encephalopathy and systemic inflammato-
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ry responses (24,25). However, the immunoglobu-
lin profile in patients suffering from acute liver fail-
ure differs between the underlying hepatic diseas-
es (26). While no difference of IgG and IgA levels in 
patients with non-paracetamol induced liver fail-
ure could be found, IgM was significantly elevated 
in patients with viral disease. Patients suffering 
from ALF caused by paracetamol intoxication had 
significant lower immunoglobulin levels, which 
explained the authors through direct drug-related 
effects on the liver. Autoantibodies were also de-
tected in coexistence with elevated IgG and espe-
cially IgM serum levels (26). However, in our study 
we could not find any significant differences in se-
rum immunoglobulin levels of patients suffering 
from ALF in comparison to ACLF or healthy indi-
viduals. 
In the United States, 45% of patients suffering 
from acute liver dysfunction recover spontaneous-
ly after intensive care, which also includes the ap-
plication of artificial liver assist devices (10). 25% 
undergo LT (10), which is the ultimate therapy of 
patients suffering from CHF too. After LT, hy-
pogammaglobulinemia can be detected in about 
30% of patients, increasing the risk of infection 
and adding to overall mortality (11,12). Gonzáles-
Quintela et al. demonstrated a decrease in serum 
immunoglobulin levels during and immediately 
after LT in 18 patients with alcoholic cirrhosis (27). 
A drop in immunoglobulin levels can be detected 
even during hepatectomy and especially after 
portal vein declamping suggesting an immediate 
increased liver catabolism (27). Months after trans-
plantation levels of IgA, IgG and IgM remained 
within normal or near-normal concentrations (27). 
In accordance with these findings we could also 
show a sudden drop of immunoglobulin concen-
trations in patients suffering from CHF also includ-
ing non-alcoholic patients, immediately after LT. 
Furthermore, antibody levels remained in the 
same range of healthy individuals over the ob-
served period of five days after transplantation. In 
contrast to those findings we could not detect any 
changes in immunoglobulin concentrations in pa-
tients with ALF or ACLF who underwent LT. How-
ever, at first we showed that patients with acute 
hepatic injury had initial antibody profile compa-
rable with healthy individuals in contrast to pa-
tients with CHF.  
Antibodies have a half-life of several days. There-
fore, it is likely that the observed immediate de-
crease of immunoglobulin levels in CHF patients 
derived from the reconstituted hepatic removal of 
antibodies, than from less antigens passing 
through the portal venous system into systemic 
circulation. This assumption is further strength-
ened by the fact, that inclusion of Hepatitis B pa-
tients, who received high concentrated IgG, into 
statistical analysis caused no change in signifi-
cance. 
The main target of peri- and postoperative immu-
nosuppressive therapy is the cell-mediated im-
mune response. Thymoglobulin and cyclosporine 
- which is given three days after LT for the first time 
- mainly lower the activity of T cells and their im-
mune response. The glucocorticoid methylpred-
nisone lowers the activity and number of T- and B 
cells. Hence, the effect of methylprednisone on 
pre LT post LT pre MARS post MARS
IgG (g/L) 4.33 (2.21-39.43) 3.49 (1.93-59.79) 2.74 (0.33-32.07) 3.20 (0.61-32.62)
IgM (g/L) 0.94 (0.24-2.49) 0.64 (0.40-3.60) 0.59 (0.25-1.61) 0.80 (0.24-6.2)
IgA (g/L) 5.70 (0.48-24.51) 4.51 (1.04-12.74) 2.30 (0.89-10.32) 1.74 (0.83-18.54)
IgE (ng/mL) 40 (30-251) 86 (41-125) 218 (57-5973) 187 (70-3337)
Data are given as median with range.
ALF - acute liver failure; ACLF - acute-on-chronic liver failure; LT - liver transplantation; MARS - molecular adsorbent recirculating 
system.
Table 4. Serum immunoglobulin levels in all patients suffering from ALF or ACLF before and after LT (23 patients) or MARS treatment 
(15 patients).
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immunoglobulin levels only becomes apparent af-
ter several days (28). Therefore, an instant dimin-
ishing effect caused by the immunosuppressive 
therapy seems implausible, since immunosuppres-
sion does not directly affect circulating antibodies. 
In addition, immunosuppressive therapy was ad-
ministered to all patients after LT, also including 
patients with ALF or ACLF. Nevertheless, the effect 
of perioperative volume administration with con-
secutive dilution cannot be entirely excluded, 
even though the diminishing effect was not obvi-
ous in patients with ALF or ACLF after LT. Moreo-
ver, there is no continuous trend regarding the 
correlation between serum antibody levels and 
other liver parameters, since significant correla-
tions were only found sporadically after transplan-
tation. 
We further investigated the effect of MARS thera-
py on the immunoglobulin profile in patients with 
an acute aggravation of hepatic failure, since the 
removal of antibodies by MARS treatment might 
be an unintended side effect. Patients with liver 
dysfunction are especially prone to infections. As a 
consequence, elimination of circulating antibodies 
by MARS treatment would further increase the risk 
of infection and add to overall mortality. However, 
we could not find any significant effects on the im-
munoglobulin profile caused by the artificial liver 
assist device treatment.
In conclusion we provide evidence for elevated 
immunoglobulin concentration in the sera of pa-
tients suffering from CHF and a reverse effect 
through LT. In contrast, MARS treatment had no ef-
fect on the immunoglobulin profile in patients 
with ALF or ACLF after one treatment cycle. How-
ever, our results warrant further larger clinical 
studies and longitudinal investigation including a 
higher number of patients and matched controls 
to assess the role of immunoglobulins in CHF ver-
sus ALF/ACLF after LT. 
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